Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-033819
Filing Date
2025-04-10
Accepted
2025-04-10 17:16:17
Documents
20
Period of Report
2025-05-19

Document Format Files

Seq Description Document Type Size
1 FORM-DEF 14A tm252345-3_def14a.htm   iXBRL DEF 14A 964442
4 GRAPHIC bc_netincome-4c.jpg GRAPHIC 70069
5 GRAPHIC bc_theravance-4c.jpg GRAPHIC 65909
6 GRAPHIC lg_theravanbiopharma-4c.jpg GRAPHIC 49258
7 GRAPHIC px_25theravproxy01pg01-bw.jpg GRAPHIC 243733
8 GRAPHIC px_25theravproxy01pg02-bw.jpg GRAPHIC 267502
9 GRAPHIC sg_rickewinningham-bw.jpg GRAPHIC 5530
  Complete submission text file 0001104659-25-033819.txt   3430869

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tbph-20241231.xsd EX-101.SCH 6129
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tbph-20241231_lab.xml EX-101.LAB 20406
23 EXTRACTED XBRL INSTANCE DOCUMENT tm252345-3_def14a_htm.xml XML 171215
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36033 | Film No.: 25829238
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)